Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for BioMarin Pharmaceutical, Inc. has moved from very attractive to fair. The company appears to be fairly valued based on its current metrics. The P/E ratio stands at 20, while the EV to EBITDA ratio is 14.21, and the PEG ratio is notably low at 0.14, indicating potential growth at a reasonable price.
In comparison to its peers, BioMarin's P/E ratio of 15.17 is lower than Illumina, Inc. at 19.09 and Elanco Animal Health, Inc. at 19.25, suggesting that BioMarin may offer better value relative to these competitors. Additionally, Halozyme Therapeutics, Inc. is also rated as fair with a P/E of 15.92, further supporting the notion that BioMarin is competitively positioned within its industry. Although specific return data is not available, the lack of negative performance relative to the S&P 500 reinforces the company's stable valuation outlook.